Lilly takes long view on Alzheimer’s drug hopeful as FDA starts expedited review

Lilly takes long view on Alzheimer’s drug hopeful as FDA starts expedited review

Source: 
BioPharma Dive
snippet: 

The Food and Drug Administration has agreed to an expedited review of Eli Lilly’s experimental Alzheimer’s disease medicine donanemab, the pharmaceutical company said Thursday.